Perrigo (PRGO) Cash from Investing Activities (2013 - 2026)
Perrigo (PRGO) posted quarterly Cash from Investing Activities of -$12.4 million for Q1 2026, up 51.75% year-over-year from -$8.2 million in Q1 2025, and up 49.39% quarter-over-quarter from -$24.5 million in Q4 2025.
Perrigo (PRGO) Cash from Investing Activities (2013 - 2026) Analysis & Trends
Perrigo (PRGO) has reported Cash from Investing Activities for 14 consecutive years, with -$12.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Investing Activities rose 51.75% year-over-year to -$12.4 million; the TTM figure through Mar 2026 stood at -$62.1 million (down 181.07% YoY), while the FY2025 annual figure was -$75.4 million, down 195.69% from the prior year.
- Cash from Investing Activities grew to -$12.4 million in Q1 2026 per PRGO's latest filing, from -$24.5 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $212.7 million in Q3 2024 and bottomed at -$2.0 billion in Q3 2022.
- Historically, Cash from Investing Activities has averaged -$120.3 million across 5 years, with a median of -$22.8 million in 2023.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities sank 8956.88% — and 2024, when it soared 792.83%.
- Perrigo's Cash from Investing Activities stood at -$26.0 million in 2022, then increased by 12.31% to -$22.8 million in 2023, then slumped by 62.72% to -$37.1 million in 2024, then soared by 33.96% to -$24.5 million in 2025, then jumped by 49.39% to -$12.4 million in 2026.
- Business Quant data shows PRGO's Cash from Investing Activities at -$12.4 million in Q1 2026, -$24.5 million in Q4 2025, and -$21.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -491.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -300.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -550.24 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 87.50 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -51.60 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -135.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -110.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Perrigo | 1.91 Bn | 1.51 Bn | 313.90 Mn | 349.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 27, 2026 | 349.40 Mn |
| Jun 27, 2026 | 349.40 Mn |
| Mar 28, 2026 | -12.40 Mn |
| Mar 28, 2026 | -12.40 Mn |
| Dec 31, 2025 | -24.50 Mn |
| Dec 31, 2025 | -24.50 Mn |
| Sep 27, 2025 | -21.40 Mn |
| Sep 27, 2025 | -21.40 Mn |
| Jun 28, 2025 | -3.80 Mn |
| Jun 28, 2025 | -3.80 Mn |
| Mar 29, 2025 | -25.70 Mn |
| Mar 29, 2025 | -25.70 Mn |
| Dec 31, 2024 | -37.10 Mn |
| Dec 31, 2024 | -37.10 Mn |
| Sep 28, 2024 | 212.70 Mn |
| Sep 28, 2024 | 212.70 Mn |
| Jun 29, 2024 | -73.30 Mn |
| Jun 29, 2024 | -73.30 Mn |
| Mar 30, 2024 | -23.50 Mn |
| Mar 30, 2024 | -23.50 Mn |